Workflow
Revance(RVNC)
icon
搜索文档
RVNC Investors Have Opportunity to Lead Revance Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
ACCESSWIRE Newsroom· 2025-01-20 23:00
文章核心观点 Revance Therapeutics公司投资者有机会牵头该公司集体诉讼,可联系Bronstein, Gewirtz and Grossman律师事务所 [1]
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Therapeutics, Inc. Lawsuit - RVNC
ACCESSWIRE Newsroom· 2025-01-18 05:30
文章核心观点 Levi & Korsinsky提醒股东Revance Therapeutics, Inc.诉讼的首席原告截止日期为2025年3月4日 [1] 分组1 - Levi & Korsinsky提醒股东Revance Therapeutics, Inc.诉讼首席原告截止日期为2025年3月4日 [1]
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
ACCESSWIRE Newsroom· 2025-01-18 01:15
法律诉讼 - Revance Therapeutics, Inc. 面临集体诉讼 Levi & Korsinsky 提醒投资者注意截至2025年3月4日的首席原告截止日期 [1]
Revance Therapeutics, Inc. Is Being Sued For Securities Law Violations And Affected Investors Are Urged To Contact The Schall Law Firm
ACCESSWIRE Newsroom· 2025-01-18 00:45
文章核心观点 - Revance Therapeutics公司因违反证券法被起诉,受影响投资者被敦促联系Schall Law Firm [1]
Contact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)
ACCESSWIRE Newsroom· 2025-01-18 00:00
法律诉讼 - Revance Therapeutics, Inc. (RVNC)面临集体诉讼 截止日期为2025年3月4日 [1]
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
ACCESSWIRE Newsroom· 2025-01-17 23:00
文章核心观点 - 律师事务所Bronstein, Gewirtz and Grossman, LLC宣布Revance Therapeutics公司股东有机会牵头集体诉讼 [1]
Levi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNC
Prnewswire· 2025-01-17 18:45
文章核心观点 Levi & Korsinsky, LLP通知Revance Therapeutics, Inc.投资者有关集体诉讼证券诉讼事宜,该诉讼旨在为受2024年2月29日至12月6日期间证券欺诈影响的投资者追讨损失 [1] 案件详情 - 被告被指控作出虚假陈述和/或隐瞒Revance严重违反与Teoxane分销协议的情况,该协议赋予Revance进口、营销、推广、销售和分销Teoxane皮肤填充产品线的独家权利 [2] - 上述情况使公司面临更高诉讼风险以及金钱和声誉损害 [2] - 上述情况增加了要约收购延迟和/或修改的风险 [2] - 公司在所有相关时间的公开声明存在重大虚假和误导性 [2] 后续安排 - 若投资者在相关时间段内在Revance遭受损失,需在2025年3月4日前请求法院指定其为首席原告,能否参与赔偿与是否担任首席原告无关 [3] - 作为集体成员,投资者可能无需支付任何自付费用或费用即可获得赔偿,参与无成本或义务 [3] 律所优势 - 过去20年,Levi & Korsinsky团队为受害股东争取数亿美元赔偿,在高风险案件中胜诉率高 [4] - 该律所擅长复杂证券诉讼,拥有超70名员工服务客户 [4] - 连续七年,Levi & Korsinsky位列ISS证券集体诉讼服务公司的美国前50大证券诉讼律所报告 [4] 联系方式 - 律所:Levi & Korsinsky, LLP [5] - 联系人:Joseph E. Levi, Esq.、Ed Korsinsky, Esq. [5] - 地址:33 Whitehall Street, 17th Floor, New York, NY 10004 [5] - 邮箱:[email protected] [5] - 电话:(212) 363 - 7500 [5] - 传真:(212) 363 - 7171 [5] - 网站:www.zlk.com [5]
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Revance Therapeutics Inc
ACCESSWIRE Newsroom· 2025-01-17 02:30
文章核心观点 Levi & Korsinsky, LLP通知投资者对Revance Therapeutics Inc展开调查 [1]
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit!
ACCESSWIRE Newsroom· 2025-01-16 23:00
文章核心观点 Bronstein, Gewirtz and Grossman, LLC宣布Revance Therapeutics, Inc.投资者有机会牵头集体诉讼 [1] 分组1 - 宣布Revance Therapeutics, Inc.投资者有机会牵头集体诉讼的公司是Bronstein, Gewirtz and Grossman, LLC [1] - 涉及的公司是Revance Therapeutics, Inc. [1]
The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.
ACCESSWIRE Newsroom· 2025-01-16 22:15
文章核心观点 Schall Law Firm邀请有损失的股东加入针对Revance Therapeutics, Inc.的证券欺诈案 [1] 分组1 - Schall Law Firm邀请有损失股东加入证券欺诈案 [1] - 案件针对Revance Therapeutics, Inc. [1]